Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.45 |
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | CDK4 | P11802 | 11/20 | 0.39 |
| ▸ | CCND1 | P24385 | 11/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.39 |
| ▸ | CDK2 | P24941 | 11/20 | 0.39 |
| ▸ | CDK7 | P50613 | 11/20 | 0.39 |
| ▸ | CCNH | P51946 | 11/20 | 0.39 |
| ▸ | CDK1 | P06493 | 8/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12703912 | 0.88 | JAK2 (0.45) | JAK2PTK2PDE5ACDK4CCND1 | |
| SCHEMBL4438464 | 0.85 | JAK2 (0.34) | JAK2PTK2CCNE1CDK2PIP4K2C | |
| SCHEMBL12703920 | 0.75 | FLT3 (0.57) | JAK2PTK2 | |
| SCHEMBL3582047 | 0.75 | CSNK1D (0.51) | CDK4CCND1CCNE1CDK2CDK7 | |
| SCHEMBL12703696 | 0.74 | PTK2 (0.46) | JAK2PTK2CDK2CDK1GAA | |
| SCHEMBL4436776 | 0.73 | JAK2 (0.35) | JAK2PTK2PDE5ACCNE1CDK2 | |
| SCHEMBL1591527 | 0.71 | JAK2 (0.37) | JAK2PTK2PDE5ACCNE1CDK2 | |
| SCHEMBL3596346 | 0.70 | NR2F2 (0.44) | PTK2CSNK1D | |
| SCHEMBL3596199 | 0.67 | CDK1 (0.55) | CDK4CCND1CCNE1CDK2CDK1 | |
| SCHEMBL6470656 | 0.67 | CCNE2 (0.37) | PDE5ACCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | claimed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | claimed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | claimed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | JAK2 629/4885PTK2 383/4885PDE5A 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.